Andrew James Stephens

US Patent:

6737236, May 18, 2004

Filed:

Jul 8, 1999

Appl. No.:

09/341337

Inventors:

Wolfgang Pieken - Boulder CO
Ken Hill - Nederland CO
Bruce Eaton - Boulder CO
Danny McGee - San Mateo CA
Kurt Vagle - Longmont CO
Larry Gold - Boulder CO
Andrew Stephens - Boulder CO

Assignee:

Proligo, LLC - Boulder CO

International Classification:

C12Q 168

US Classification:

435 6, 435174, 568767, 4241931, 534766, 536 221, 530350

Abstract:

This invention discloses a novel method for conjugating macromolecules to other molecular entities. Specifically, this invention discloses a method for conjugating or derivatizing macromolecules, such as oligonucleotides and proteins, using cycloaddition reactions, such as the Diels-Alder reaction or 1,3-dipolar cycloadditions. Included in the invention are the novel bioconjugated macromolecules that can be prepared according to the method of the invention.

US Patent:

7094535, Aug 22, 2006

Filed:

Dec 18, 2001

Appl. No.:

10/024997

Inventors:

Judy Ruckman - Boulder CO, US
Larry Gold - Boulder CO, US
Andrew Stephens - Boulder CO, US
Nebojsa Janjic - Boulder CO, US

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C12Q 1/68
G01N 33/567
C07H 21/04

US Classification:

435 6, 436504, 536 231, 536 2431

Abstract:

Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.

US Patent:

20070010473, Jan 11, 2007

Filed:

Aug 22, 2006

Appl. No.:

11/508024

Inventors:

Judy Ruckman - Boulder CO, US
Larry Gold - Boulder CO, US
Andrew Stephens - Boulder CO, US
Nebojsa Janjic - Boulder CO, US

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

A61K 48/00

US Classification:

514044000

Abstract:

Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.

US Patent:

20080207523, Aug 28, 2008

Filed:

Sep 7, 2007

Appl. No.:

11/851789

Inventors:

Matthias Friebe - Berlin, DE
Andrew Stephens - Boulder CO, US
Ananth Srinivasan - Berlin, DE
Maren Hecht - Berlin, DE

International Classification:

A61K 38/08
C07K 7/06
A61P 35/00
C07K 1/00

US Classification:

514 15, 530329, 530328, 530327, 530333, 514 16

Abstract:

The object of the present invention is solved by compositions of peptide linkers and their use for synthesis and annealing of aptamer oligonucleotides in form of dimers. The present invention in particularly provides said compositions for the use as a diagnostic and/or therapeutic agent.In another preferred embodiment the present invention relates to a kit for preparing a radiopharmaceutical preparation, said kit comprising a vial comprising a quantity of the compound according to the invention.A further preferred embodiment of the present invention relates to methods of producing said compounds, comprising synthesis of said compound in an automated peptide synthesizer.In another preferred embodiment the present invention concerns the use of said compounds according to the present invention for the manufacture of a medicament, preferably for diagnosis or therapy of proliferative diseases.In a further preferred embodiment the present invention concerns methods for treating or diagnosing patients administering or utilizing the compounds according to the present invention.

US Patent:

63313944, Dec 18, 2001

Filed:

Jul 29, 1999

Appl. No.:

9/364543

Inventors:

Judy Ruckman - Boulder CO
Larry Gold - Boulder CO
Andrew Stephens - Boulder CO
Nebojsa Janjic - Boulder CO

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C12Q 168
C12P 1934
C07H 2102
C07H 2104

US Classification:

435 6

Abstract:

Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.

US Patent:

56889356, Nov 18, 1997

Filed:

May 3, 1995

Appl. No.:

8/433126

Inventors:

Andrew Stephens - Denver CO
Dan J. Schneider - Boulder CO
Larry Gold - Boulder CO
Ulrich Speck - Berlin, DE

Assignee:

NeXstar Pharmaceuticals, Inc. - Boulder CO
Schering Aktiengesellschaft - Berlin

International Classification:

C07H 2102
C07H 2104
C12Q 168
C12P 1934

US Classification:

536 231

Abstract:

This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to peripheral blood mononuclear cells (PBMC), fibrin clots, and carotid arteries are described.

US Patent:

57635668, Jun 9, 1998

Filed:

May 3, 1995

Appl. No.:

8/433585

Inventors:

Kirk B. Jensen - Boulder CO
Hang Chen - Boulder CO
Kevin N. Morris - Schwarzach, AT
Andrew Stephens - Denver CO
Larry Gold - Boulder CO

Assignee:

NeXstar Pharmaceuticals, Inc. - Boulder CO

International Classification:

C07K 500
C07K 1300
C07H 2102
C12P 1934

US Classification:

530350

Abstract:

This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, glioblastomas, and lymphomas are described.

US Patent:

57123756, Jan 27, 1998

Filed:

May 3, 1995

Appl. No.:

8/434001

Inventors:

Kirk B. Jensen - Boulder CO
Hang Chen - Boulder CO
Kevin N. Morris - Schworzach, AT
Andrew Stephens - Denver CO
Larry Gold - Boulder CO

Assignee:

NeXstar Pharmaceuticals, Inc. - Boulder CO

International Classification:

C07K 114
C12Q 168
C12P 1934
C07H 2104

US Classification:

530412

Abstract:

This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, glioblastomas, and lymphomas are described.